HCRN MEL16-252
Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Status: Closed to Accrual
Learn more:
- clinicaltrials.gov: #NCT03241186
- News release
Study Contact: studies@hoosiercancer.org; (317) 921-2050.
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter